HC Wainwright Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $40.00

Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by HC Wainwright from $50.00 to $40.00 in a report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($6.07) EPS, FY2026 earnings at ($6.27) EPS, FY2027 earnings at ($6.97) EPS, FY2028 earnings at ($5.09) EPS and FY2029 earnings at ($2.90) EPS.

CRBP has been the subject of a number of other research reports. Jefferies Financial Group reduced their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Wedbush reissued an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Finally, William Blair assumed coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.88.

Corbus Pharmaceuticals Price Performance

NASDAQ:CRBP opened at $6.45 on Wednesday. The company’s fifty day moving average price is $6.33 and its 200-day moving average price is $10.85. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $61.90. The firm has a market capitalization of $78.90 million, a P/E ratio of -1.38 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.13). Equities analysts anticipate that Corbus Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,172 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 2,195 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Corbus Pharmaceuticals during the fourth quarter worth about $84,000. Deutsche Bank AG lifted its position in Corbus Pharmaceuticals by 46.8% in the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 2,616 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Corbus Pharmaceuticals in the fourth quarter valued at about $101,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.